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Abstract
Background Type 2 diabetes mellitus (T2DM) is a signif-
icant global public health problem affecting more than 285
million people worldwide. Over 70% of those with T2DM
live in developing countries, and this proportion is
increasing annually. Evidence suggests that lifestyle and
other nonpharmacological interventions can delay and even
prevent the development of T2DM and its complications;
however, to date, programs that have been specifically
adapted to the needs and circumstances of developing
countries have not been well developed or evaluated.
Purpose The purpose of this article is to review published
studies that evaluate lifestyle and other non-pharmacological
interventions aimed at preventing T2DM and its complica-
tions in developing countries.
Methods We undertook an electronic search of MEDLINE,
PubMed, and EMBASE with the English language restric-
tion and published until 30 September 2009.
Results Nine relevant publications from seven studies were
identified. The reported interventions predominantly used
counseling and educational methods to improve diet and
physical activity levels. Each intervention was found to be
effective in reducing the risk of developing T2DM in
people with impaired glucose tolerance, and improving
glycemic control in people with T2DM.
Conclusions The current evidence concerning the preven-
tion of T2DM and its complications in developing countries
has shown reasonably consistent and positive results;
however, the small number of studies creates some
significant limitations. More research is needed to evaluate
the benefits of low-cost screening tools, as well as the
efficacy, cost-effectiveness, and sustainability of culturally
appropriate interventions in such countries.
Keywords Type 2 diabetes . Complications . Prevention .
Developing countries
Introduction
Type 2 diabetes mellitus (T2DM) is a significant global
public health problem [1, 2]. The International Diabetes
Federation recently reported that the number of people with
diabetes will escalate from 285 million in 2010 to 438
million by 2,030, with more than 70% of cases already
from developing countries [2]. Despite a number of
significant global and regional initiatives being undertaken
to prevent diabetes and diabetes-related complications [3–
7], seven out of the top ten countries with the greatest
number of people living with diabetes are low- or middle-
income countries. These include China, India, Russia,
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Brazil, Pakistan, Indonesia, and Bangladesh [8–11], with
China now having the largest number of individuals with
diabetes (92.4 million) in the world [8].
Each year, almost four million deaths are directly
attributable to diabetes, constituting 6.8% of the total global
(all-age and all-cause) mortality [12, 13]. Diabetes is the
fourth leading cause of disease-related death and almost
80% of diabetes-related deaths occur in developing
countries. It has been projected that diabetes-related deaths
will increase by 50% in the next 10 years if no urgent action
is taken [14]. T2DM poses a significant economic burden to
individuals, families, health systems, and nations, particular-
ly in resource-poor countries [14, 15]. Despite this, over
80% of the world’s diabetes care-related expenditure occurs
in developed countries [16]. Given the rapidly escalating
financial and societal costs associated with diabetes care in
developing countries, where resources to address the disease
are severely limited, there is an urgent need for the
development, implementation, and evaluation of programs
to prevent T2DM and its complications [4].
Since the concept of T2DMprevention on a mass scale was
first proposed early in the twentieth century [17], and was
more recently emphasized by the World Health Organization
(WHO) [18] and other international organizations, a number
of very well-conducted intervention trials have now evalu-
ated the prevention of diabetes and its complications in
developed countries. These trials include the Malmo Feasi-
bility Study in Sweden [19], the Finnish Diabetes Prevention
Study (DPS) [20–22] and the US Diabetes Prevention
Program (DPP) [23]; all of which have demonstrated
comparable efficacy, by reducing the risk of developing
T2DMby up to 63% in lifestyle intervention groups compared
with controls. A recent systematic review and meta-analysis
by Gillies et al. confirmed these findings, reporting that non-
pharmacological interventions were effective in reducing the
risk of T2DM in people with impaired glucose tolerance (IGT)
by up to 60% compared with control groups [24].
Trials focused on the prevention of T2DM complications
conducted in developed countries have not directly examined
the effects of non-pharmacological interventions on compli-
cation incidence. However, studies have demonstrated that
non-pharmacological interventions are effective in reducing
glycemic levels in people with T2DM [19, 20] and work from
the UK and Japan indicates that optimal control of glycemic
levels in people with newly diagnosed T2DM can reduce the
development of complications [25, 26].
Despite the evidence concerning prevention of T2DM and
its complications in developed countries, the translation of
these programs to developing countries, where resources are
limited to address the problem, still presents a very significant
challenge. Therefore, it is important to develop and evaluate
culturally appropriate interventions in developing countries
[3, 27]. This paper reviews the study characteristics, efficacy,
and cost-effectiveness of those non-pharmacological inter-
ventions aimed at preventing T2DM and its related compli-
cations in developing countries.
Methods
Search Strategy
We undertook an electronic search of MEDLINE, PubMed,
and EMBASE with the search terms “Diabetes Mellitus
Type 2,” “Glucose Intolerance,” “Primary Prevention,”
“Secondary Prevention,” “Diabetes Complications,” and
“Lifestyle Intervention.” These search terms were com-
bined with the search term “Developing Countries” to
identify relevant articles. In addition, we performed a
search of policy and program documents developed by
different national and international organizations. Further-
more, all relevant reference lists from the main papers were
hand searched for additional papers of interest. The article
search, inclusion and selection process is shown in Fig. 1.
Inclusion Criteria
The search was restricted to English language with papers
published until 30 September 2009. We applied the World
Bank 2008 classification criteria [28] to identify developing
countries. Those studies/trials that employed lifestyle or
non-pharmacological interventions conducted in developing
countries with a glucose measure as a primary outcome
were included. There was no restriction on sample size or
duration of the intervention.
Information Assessment
Two independent reviewers examined each full-text paper
for eligibility and extracted and tabulated all relevant
information. Any differences were resolved by discussion
and consensus with other authors. Inclusion or exclusion of
the studies was determined by consensus between authors.
The information assessment and synthesis were primarily
based on the main findings of the publications.
Results
We initially identified 247 research articles by Medline,
PubMed, and EMBASE searches. After a review of the
titles and abstracts, 84 papers closely matched our inclusion
criteria. The full papers were examined, however, 75 papers
did not meet our inclusion criteria (i.e., evaluation of non-
pharmacological interventions aimed at prevention of the
development of T2DM or its associated complications, the
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inclusion of blood glucose or glycosylated hemoglobin
(HbA1c) as a primary outcome and the study being
undertaken in a developing country), so they were subse-
quently excluded. Consequently, nine publications from seven
studies were included in this review. A summary of each
intervention and the findings are presented in this section. The
main findings of the studies are divided into four subsections:
(1) sample characteristics, (2) intervention or program
characteristics, (3) effectiveness of the programs and (4)
cost-effectiveness. The key sample characteristics and the
findings of the study are summarized in Tables 1 and 2 and
intervention characteristics in Tables 3 and 4.
Sample Characteristics
Prevention of the Development of T2DM Five relevant
publications from three studies assessing effectiveness of
the lifestyle interventions for prevention of the development
of T2DM were identified. There was significant heteroge-
neity in the sample characteristics, such as sample size, age,
inclusion criteria, type of sample, and length of follow-up,
across the studies (Table 1). The Da-Qing study, a
randomized controlled trial (RCT) designed to prevent
diabetes progression in people with IGT in an urban area in
China, recruited 283 men and 247 women over 25 years of
age (mean age, 45±9.1 years) [29, 30]. The active
intervention of this program lasted 6 years. The Indian
Diabetes Prevention Program (IDPP-1) was a 3-year
prospective RCT that recruited an urban population aged
35–55 years old with persistent IGT [31]. The sample of
421 men and 110 women were leaner and yet more insulin
resistant than the subjects included in the Finnish DPS [20–
22] and US DPP [23] studies. A community-based diabetes
prevention study by Balagopal et al., undertaken in rural
India, recruited 703 villagers aged 10–92 years old [32].
The mean age of participants was 35.8±17.0 years and
follow-up lasted 7 months.
Blood Glucose Measurements and Criteria for Participant
Selection in Studies to Prevent the Development of
T2DM The Da-Qing and IDPP-1 studies used oral glucose
tolerance tests to assess blood glucose levels. The Da-Qing
study [29] implemented the WHO 1985 criteria [33] to
survey and identify people with normoglycemia, impaired
fasting glucose (IFG), IGT, and T2DM. The IDPP-1 [31]
used the WHO 1999 criteria [34] and the community-based
program in India [32] used a glucometer to measure blood
glucose and the American Diabetes Association (ADA)
criteria 2005 to classify IGT [35]. The WHO 1999 and the
ADA 2005 use the same criteria for classifying people with
diabetes, IGT and IFG, however, the WHO 1985 classifi-
cation included higher cut-off values for fasting and 2-h blood
glucose levels compared with the later WHO 1999 and ADA
2005 criteria.
Inclusion criteria 
used: Lifestyle or non-
pharmacological 
interventions in 
developing countries 
published until 30 
September 2009. 
Written only in English 
language 
84 articles retrieved for more 
detailed evaluation (abstract 
+full articles examined)
9 articles were included
Prevention of the development 
of T2DM: 5 
Lifestyle management: 4 
Cost effectiveness: 1 
Management of T2DM: 4 
Interpersonal education based: 2 
Cellular phone/ internet based: 2 
75 were excluded  
Non-interventions: 31 
Conducted in developed 
countries: 24 
Reviews: 16 
Glucose measure was 
not primary outcome: 2 
Study protocol: 2 
Search engine: MEDLINE, PubMed and EMBASE searches
Main search terms: 
“Diabetes Mellitus Type 2”, “Glucose Intolerance”, “Primary Prevention” 
“Secondary Prevention”, “Diabetes Complications”, “Lifestyle Intervention”, 
“Developing Countries” 
247 articles identified (title and 
abstract reviewed) 
163 papers excluded (on 
the basis of title and 
abstract, did not fulfil 
inclusion criteria) 
Fig. 1 Flow chart showing
articles search, inclusion criteria,
and selection process
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Prevention of Diabetes Complications Four relevant studies
assessing effectiveness of lifestyle interventions for the
prevention of diabetes complications were identified. The
sample characteristics of the intervention studies preventing
the development of complications in people with T2DM
were heterogeneous (Table 2). One RCT conducted in
China aimed at improving glycemic control among over-
weight people with diabetes recruited 150 individuals, with
100 in the intervention arm and 50 in the control group
[36]. With a mean age of 51±1.0 years, this sample was
followed up for 6 months. A hospital-based RCT in
Thailand recruited 147 adults over 35 years of age [37].
This follow-up lasted 6 months. Of the two RCTs
conducted in Korea, one recruited 51 patients [38] and the
other 34 patients with T2DM [39], each with a mean age of
47 years. The first sample was followed up over 3 months
and the second over 6 months.
Intervention Characteristics
Prevention of the Development of T2DM The three studies
undertaken to prevent the development of T2DM in
developing countries included a range of interventions
(Table 3). The Da-Qing study comprised three lifestyle
intervention groups (diet, exercise, and diet+exercise), with
one control group [29]. Overweight participants were
advised to improve healthy food habits and increase
physical activity through individual and small-group ses-
sions, until they had reached a target body mass index of
23 kg/m2. The IDPP-1 included a lifestyle intervention,
medication (metformin tablets) group, combined lifestyle
and metformin group and control group [31]. Participants in
the lifestyle intervention group received individual advice
regarding diet modification and exercise promotion. The
intervention by Balagopal et al. comprised an educational
intervention for the rural community; however, no control
condition was included [32]. Culturally sensitive and
linguistically appropriate sessions on dietary modification,
physical activity, and simple relaxation breathing techni-
ques constituted the main components of this intervention.
Prevention of Diabetes Complications There was a signifi-
cant variation in the interventions employed across the four
studies aimed at preventing T2DM complications in devel-
oping countries (Table 4). Two studies included an educa-
tional intervention [36, 37] and two involved telemedicine-
based nurse-led educational intervention [38, 39]; all with
Table 3 Summary of study intervention characteristics for prevention of development of T2DM
Study/Ref Intervention characteristics Intensity, duration, and regularity
Da-Qing,
China
[29, 30]
Intervention groups—received individual/small-group counseling,
delivered by trained physicians, nurses, and technicians
1 individual counseling session
Diet group—those with body mass index (BMI) of ≥25 kg/m2
advised to lose weight, through goal setting on healthy diets.
Those with BMI of <25 kg/m2 encouraged to eat healthy diets
with prescribed proportions of carbohydrates, fat, and protein
Weekly small-group counseling
sessions
for 1 month, monthly for 3 months
and then once every 3 months
Exercise group—advised to increase amount of leisure time physical exercise
Diet+exercise group—received both interventions as above
Control group—received usual care (general information on diabetes/IGT,
brochures containing information on improving diet/physical activity)
IDPP-1, India
[31, 40]
Intervention groups—received individual counseling, followed up by telephone 1 individual counseling at the
beginning of the studyLifestyle group—those performing “moderate” activity (physical labor/walk or
cycle for >30 min/day/perform exercise regularly) advised to continue
routine activities. Those performing sedentary/light physical activity
advised to walk briskly for ≥30 min/day
Telephonic contact after
2 weeks or by letter
Advice on diet modification given, including reduction in total calories and
refined carbohydrates/fats, avoidance of sugar, and inclusion of fiber-rich foods
Monthly telephonic contacts personal
sessions at 6 monthly intervals
Metformin group—received metformin tablets for 3 months and
provided diaries to record daily intake of tablets
Lifestyle+metformin group—received both interventions as above
Control group—received advice on standard healthcare
Community
based, India
[32]
Individual face-to-face culturally sensitive (Tamil language) educational sessions
on dietary modification (increasing fiber, reducing fat, portion control), increasing
physical activity, and relaxation breathing techniques conducted
10 face-to-face individual education
sessions
Group events for reinforcement
Group events, such as cooking/physical activity demonstrations,
organized as reinforcement
Additional counseling sessions for
individuals with impaired FBG
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comparison control groups. The educational interventions
provided information on behavioral and lifestyle change. In
one study, individuals in the intervention group received
monthly group sessions on the management of diabetes and
lifestyle modification delivered by an experienced nutrition-
ist [36]. This group also received weekly consultation
sessions on diet and medical evaluation. In comparison, the
control group received monthly group sessions comprising
diabetes education. In another study, individuals in the
intervention group participated in small-group diabetes
education classes and received a patient education manual
[37]. A researcher also conducted home visit sessions for
each of these participants. The control group, in contrast,
received usual nursing care before they began diabetes
education classes at the end of the study. The two
telemedicine-based nurse-led educational interventions com-
prised education and reinforcement of healthy diet, physical
exercise, and medication adjustment to those participants in
the intervention groups [38, 39]. The reminders for frequent
self-monitoring of blood glucose levels were sent to each
participant in the intervention groups, using short message
services via cellular mobile phone.
Intervention Effectiveness
Prevention of the Development of T2DM Each study
showed significant reductions in the development of
T2DM in the intervention group compared with controls.
The Da-Qing study successfully reduced the risk of
developing T2DM up to 46% in the lifestyle intervention
group compared with the control group [29]. The 20-year
follow-up showed that the group-based lifestyle interven-
tion implemented over 6 years prevented or delayed
diabetes for up to 14 years, although the long-term effects
on reduced cardiovascular disease morbidity and mortality
were less clear [30]. The IDPP-1 reported high rates of
progression of IGT to T2DM in control participants (18.3%
Table 4 Summary of study intervention characteristics for prevention of complications
Study/Ref Intervention characteristics Intensity, duration, and regularity
Sun et al.,
China [36]
Intervention group—received monthly group sessions on diabetes management/
lifestyle modification delivered by an experienced nutritionist
Weekly individual consultation sessions
(30 min each) for 6 months
Participants received weekly consultation sessions on diet and medical
evaluations including assessment of adverse events, review of blood
glucose measurements and adjustment of medications
Additional monthly group sessions
Participants were provided with blood glucose monitors
Control group—received monthly group sessions providing diabetes education
Wattana et al.,
Thailand [37]
Intervention group—participated in small-group diabetes education classes
(120 min) and discussions (90 min)
1 small-group diabetes education class,
followed by 4 small-group discussions
Received individual home visits from researcher (45 min) and
patient education manual
Participants were taught how to make lifestyle changes, monitor symptoms,
record, and interpret their blood glucose levels, blood pressure, and blood
lipid levels
2 individual home visit sessions in
6 months
Control group—received usual nursing care, health education during waiting
time at hospital and diabetes education class at the end of the study
Kim,
Korea [38]
Intervention group—received education and reinforcement on diet, exercise,
medication adjustment, and frequent self-monitoring of blood
glucose levels led by nurse via mobile phones and internet
Weekly individual sessions via cellular
phone and Internet for 6 months
Participants were provided with blood glucose monitors
Control group—met an endocrinologist once or twice during a 3-month study
Those in control group who visited program intervention center received advice
on medication, medication dosage, and lifestyle modification from
endocrinologist
Kim and Song,
Korea [39]
Intervention group—received education and reinforcement on diet, exercise,
medication adjustment, and frequent self-monitoring of blood glucose
levels led by nurse via mobile phones and internet
Weekly individual sessions via cellular
phone or wired Internet for 3 months
Participants were provided with blood glucose monitors
Control group—met an endocrinologist 2–4 times during a 6-month study
Those in control group who visited program intervention center received advice
on medication, medication dosage, and lifestyle modification from
endocrinologist
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incidence per year), while both lifestyle modification and
medication reduced T2DM incidence, with a relative risk
reduction of 28.5% and 26.4%, respectively, over the 3-year
study [31]. Interestingly, the IDPP-1 program did not show
an additional benefit of combined lifestyle intervention and
medication. The community-based, non-pharmacological
diabetes prevention program in rural India was successful
in reducing fasting blood glucose levels in adults with IFG
by 11%, in youths by 17%, and in adults with T2DM by
25% over the 7-month study, although the numbers in each
group were small [32]. In addition, the authors reported
improvements in obesity parameters and dietary intake.
Prevention of Diabetes Complications Significant improve-
ments were observed in glycemic control across the range
of diabetes complications prevention studies. One RCT in
China improved glycemic control and markers of cardio-
vascular health in people with T2DM [36]. This program
reduced HbA1c levels by 0.8% in the intervention group,
compared with an elevation of 0.1% in the reference group
over the 6-month study timeframe. Participants in both the
intervention and reference groups achieved modest weight
loss of 3.7% and 2.5%, respectively. The hospital-based
RCT in Thailand demonstrated the efficacy of educational
interventions by reducing HbA1c levels by 0.68% in the
intervention group, compared with 0.07% in the control
group over 6 months [37]. The program also demonstrated
reductions in risk factors for coronary heart disease of
4.83% in the intervention group, as opposed to 1.54% in
the control group. Similarly, the two RCTs conducted in
Korea showed reductions in HbA1c levels in adults with
T2DM [38, 39]. One demonstrated reduced HbA1c levels
of 1.15% in the intervention group compared with an
elevation of 0.07% in the control group over 3 months [38,
39], and the other reduced HbA1c levels by 1.09% in the
intervention group, compared with no changes in the
control group over the 6-month study [38, 39].
Cost-effectiveness
Prevention of Development of T2DM The economic eval-
uation of the IDPP-1 was the only cost-effectiveness study
of a diabetes prevention intervention program identified in
a developing country [40]. This work concluded that the
lifestyle intervention was cost-effective for preventing
diabetes among high-risk individuals. The total cost spent
to identify one subject with IGT was the equivalent of US
$117. The total direct medical cost of the intervention in
different groups over the 3-year intervention period was US
$61 per subject in the control group, US $225 with lifestyle
modification and US $270 with the lifestyle modification+
medication group. The cost of the intervention to prevent
one case of diabetes was US $1,052 with lifestyle modifica-
tion and US $1,359 with lifestyle modification+medication.
In addition, the number of individuals needed to treat to
prevent a case of diabetes was 6.4 with lifestyle modification
and 6.5 with lifestyle modification+medication.
Prevention of Development of Complications No cost-
effectiveness studies for preventing T2DM complications
in developing countries were identified.
Discussion
Diabetes in developing countries contributes to an increas-
ing proportion of the total global burden of diabetes [2, 14,
41]. Prevention studies have now been conducted in China
[29, 30, 36], India [31, 32, 40], Thailand [37], and Korea
[38, 39]. Despite the limited number of studies, these
studies do provide some important information concerning
the efficacy and cost-effectiveness of non-pharmacological
interventions for the prevention of T2DM and its related
complications in developing countries.
Prevention of the Development of T2DM
The non-pharmacological interventions in China [29, 30]
and India [31, 32] have demonstrated that the lifestyle
interventions can result in significant reductions of risk for
the development of T2DM in people with IGT or IFG. The
Da-Qing study and the IDPP-1 each reported a significant
relative risk reduction in the development of T2DM in the
intervention groups, however these were substantially lower
than shown in similar trials conducted in developed
countries, including the Finnish DPS [20–22] and US
DPP [23]. These latter trials have reported a relative risk
reduction of 58% in diabetes incidence in the lifestyle
intervention groups over approximately 3-year intervention
periods. The lifestyle interventions in these trials focused
on weight loss, intake of healthy diet, and promoting
modest physical activity, and were delivered by a nutrition-
ist [20] and special educators (“case managers”) [23].
Although the risk reduction was lower in the developing
countries, the progression of T2DM incidence in the control
group was observed to be greater in the IDPP-1 [31] than in
developed countries (IDPP-1 at 18.3% compared with DPS
at 6% [42] and DPP at 11% per year [23]). Therefore, any
reduction in the progression of T2DM in developing
countries is particularly important. There are likely to be
numerous explanations for the higher effectiveness in
developed countries compared with low-income countries.
For example, the existing structure of healthcare systems in
developed countries provides a framework for effective
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intervention studies [43]. Access to healthcare services is
likely to be another important factor, as is the reduced level
of health literacy in some developing countries. Poor
adherence to standard diabetes care may be lower in
developing countries as a result of competing priorities that
are not present in developed countries.
It is interesting to note that, even in samples with
comparable age ranges and obesity levels, Indian cohorts
demonstrated an elevated progression rate of T2DM
compared with Chinese groups [29]. High prevalence of
diabetes and elevated levels of insulin resistance in South
Asian populations [44] could have resulted in the observed
high rates of T2DM incidence in the control group in the
Indian sample. The China Da-Qing intervention [29, 30]
was reported to be more effective than the IDPP-1 [31]. The
increased intensity and the mode of intervention delivery
through trained physicians and nurses in the China Da-Qing
study are likely to have influenced these differences. In
terms of features of the interventions with higher efficacy,
the inclusion of exercise, either alone or in conjunction with
diet [29–32], demonstrated the greatest improvements in
risk reduction of diabetes.
Prevention of Diabetes Complications
Maintaining glycemic control, in particular HbA1c levels
lower than 7% [45–47], is important for preventing
diabetes-related complications. Early effective intervention
for the management of hyperglycemia, hypertension, and
dyslipidemia can reduce the risk of developing diabetes-
related complications [48]. The non-pharmacological edu-
cational interventions in China [36], Thailand [37], and
Korea [38, 39] demonstrated reductions of HbA1c levels
and other cardiovascular disease risk factors, which might
facilitate improvements in diabetes control and prevent
disease-related complications. These findings are supported
by other studies conducted in developed countries, which
have resulted in reduced HbA1c levels, adiposity, and
blood pressure in the intervention compared with control
groups [25, 26, 49]. For example, a diabetes education and
self-management program reduced HbA1c levels by 1.49%
in people with newly diagnosed diabetes [25], and a weight
reduction and exercise program for older African-American
adults reduced HbA1c levels by 1.1% in the intervention
compared with control groups [26]. Telehealth-delivered
educational interventions in developing countries were also
shown to be effective in reducing HbA1c levels in adults
with T2DM [38, 39]. Previous work from developed
countries has found similar results, demonstrating de-
creased HbA1c levels in patients receiving telephone-
based nurse support programs [50–52].
The interventions conducted in developed countries that
focused on prevention of diabetes-related complications
[25, 26, 49–52] have shown greater improvements in
glycemic control compared with those in developing
countries [36–39] (reduction of HbA1c level 0.9–1.7%
compared with 0.7–1.1%). As discussed in the earlier
paragraph in relation to primary prevention, there are
multiple explanations for lower efficacy of such trials in
developing countries compared with developed countries.
In addition, within the studies in developing countries, the
telehealth-delivered educational interventions [38, 39]
reported greater reductions in HbA1c compared with those
with interpersonal education-based programs [36, 37]. It is
possible that the delivery of the interventions via trained
nurses in the telehealth studies had an impact on the
differentials in efficacy across these studies.
Previous studies have shown that, in addition to
lifestyle interventions, pharmacological interventions are
effective in the prevention of diabetes-related complica-
tions [53–58]. The UKPDS, one of the most widely
known studies, showed that anti-hypertensive medications
reduced macrovascular endpoints by 37% and diabetes-
related mortality by 32% [53]. Similarly, a Danish study
conducting a multifactorial intervention, implementing
behavioral modification alongside pharmacological thera-
py, found CVD risk reductions of up to 50% in the
intervention compared with the conventional treatment
group [57]. Although the studies included in this review
did not implement pharmacological interventions, other
studies from low- and middle-income countries have
shown similar results to those from the developed world
with medication therapy within their programs [59–62].
Therefore, the existing evidence indicates that the use of
medication is also important in the management of
diabetes and preventing the related complications.
Cost-effectiveness of Programs
The 3-year IDPP-1 confirmed that a non-pharmacological
intervention was cost-effective for preventing diabetes
among high-risk Indian adults [40]. All the costs incurred
in the different intervention groups of IDPP-1 were
substantially lower and more cost-effective than the costs
incurred in the US DPP [63], where the placebo group cost
US $218, the lifestyle intervention group cost US $2,919
and medication group cost US $2,681 over the 3-year
intervention period. Sparse data are available examining the
costs and cost-effectiveness of the interventions related to
prevention of T2DM and its complications, and the studies
that do exist come predominantly from developed countries
[19, 63–65]. However, the cost and the cost-effectiveness
estimations from the IDPP-1 study suggest that non-
pharmacological interventions for the prevention of
T2DM in developing countries are, in absolute terms,
cheaper and more cost-effective compared with studies
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from the developed world, such as the DPP [63]. This
evidence should encourage other developing countries to
develop and implement cost-effective, non-pharmacological
interventions to stem the escalating problem of T2DM and
diabetes-related complications.
Limitations of the Studies/Programs
Prevention of the Development of T2DM The two Indian
studies [31, 32] and the Da-Qing [29] study have some
important limitations. Most importantly, these studies
identified high-risk individuals using IGT or IFG classi-
fications, which employ relatively expensive screening
methods that require individuals to fast and undergo
blood tests. In countries such as China and India, where
rates of diabetes are extremely high, it is not feasible or
cost-effective to screen everyone using such expensive
screening methods for diabetes. Low-cost screening
methods such as short questionnaires to identify high-
risk individuals need to be developed and tested in
diabetes prevention programs. Furthermore, in the IDPP-1,
only one fifth of the subjects were female [31]; yet, the
number of males and females in India with IGT are
comparable [2, 9]. In addition, this program selected a
sample from a middle class working people with persistent
IGT in an urban setting; however it did not include people
from rural areas, where two thirds of the population of
India live, so generalizability to the whole population is
problematic. Although the IDPP-1 estimated the direct
medical costs and cost-effectiveness of the program [40],
it did not estimate the longer-term cost-effectiveness of the
program and the indirect costs which are often many times
higher than the direct medical costs. The study by
Balagopal et al. did not include a control group, comprised
very small numbers of high-risk participants, and lacked
sufficient follow-up (7 months) to determine the sustained
effect of the intervention [32]. The Da-Qing study
achieved a longer-term follow-up; however, it did not
report the estimated cost and cost-effectiveness of the
program [29, 30].
Prevention of Diabetes Complications Amajor limitation of
these studies was the short follow-up periods, which varied
between 3 [38] and 6 months [36, 37, 39]. This meant the
sustainability of the intervention effects could not be
evaluated [36–39]. The time frame did not allow an
evaluation of the efficacy of the trials on incidence of
complications, only the observation of reduced risk factors
associated with the development of complications. In
addition, the hospital-based study in China had a large
discrepancy in the number of participants in the control and
intervention groups [36]. The two Korean RCTs included
sample sizes (n=51 and 34) that were too small to reliably
establish intervention effects, particularly over the short
follow-ups of 3 and 6 months, respectively [38, 39].
Future Directions
Given the escalating burden of noncommunicable diseases
in low- and middle-income countries [66], research must
begin to focus more heavily on effective chronic disease
interventions [43]. Future programs to prevent diabetes and
its associated complications in developing countries should
focus on the appropriate development, adaptation, and
implementation of efficacious, cost-effective intervention
methods from developed and developing countries.
However, it is also important to evaluate programs that
combine more traditional educational and behavioral
methods with peer support, telehealth, and other more
contemporary approaches that are now being widely
utilized around the world [67–72]. To date, diabetes
prevention trials in developed as well as developing
countries have primarily targeted those people with
diagnosed pre-diabetes [20, 23, 29, 31]; however, in
resource-constrained settings, it is not feasible to rely on
the identification of such high-risk individuals using blood
tests so the development of valid and reliable self-report
risk assessment tools is also required [73]. In addition, it is
very important to develop linguistically appropriate and
context-specific lifestyle interventions that are tailored to
meet the cultural, religious, and socioeconomic needs of
the target communities, with long-term implementation to
enable the sustainability of the targeted intervention
outcomes.
It is also necessary to consider the development and
evaluation of programs that link with local community
resources, relevant non-government organizations, and in
particular, local health services. Interventions focused on
chronic disease prevention and management in developing
countries must engage healthcare systems to initiate the
improvements and reform that are urgently required to
support the long-term primary and secondary prevention
and care of those at risk and with these diseases [43].
Conclusions
We conclude that, despite the escalating burden of
T2DM in developing countries, the current evidence
concerning the prevention of T2DM and its complica-
tions in these countries still remains quite limited.
Nevertheless, there is an urgent need to stem the growing
epidemic of T2DM in rapidly developing countries that
face significant resource constraints. This must be
achieved by linking a significant primary prevention
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effort in all countries with the use of low-cost behavioral
medicine and related approaches to screen and identify
high-risk individuals, followed by the development,
implementation, and evaluation of community-based
programs that are culturally relevant and cost-effective.
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